BioKnow
@bioknow.bsky.social
Save the date! The London Biotechnology Show returns on 18-19 June 2025 at ExCeL London. 📷
Key Speakers include Jakob E. Larsen (Novo), Jimmy Toulas (Pfizer), Thomas Balkizas (Microsoft), and more!
Connect, innovate & shape the future of biotech!
Register now: buff.ly/65vWn7D
Key Speakers include Jakob E. Larsen (Novo), Jimmy Toulas (Pfizer), Thomas Balkizas (Microsoft), and more!
Connect, innovate & shape the future of biotech!
Register now: buff.ly/65vWn7D
May 14, 2025 at 10:03 AM
Save the date! The London Biotechnology Show returns on 18-19 June 2025 at ExCeL London. 📷
Key Speakers include Jakob E. Larsen (Novo), Jimmy Toulas (Pfizer), Thomas Balkizas (Microsoft), and more!
Connect, innovate & shape the future of biotech!
Register now: buff.ly/65vWn7D
Key Speakers include Jakob E. Larsen (Novo), Jimmy Toulas (Pfizer), Thomas Balkizas (Microsoft), and more!
Connect, innovate & shape the future of biotech!
Register now: buff.ly/65vWn7D
Top Pharma Companies by 2024 Pipeline Size 🧬
Check out the latest data from the Citeline Pharma R&D Review 2024, showcasing the top global pharmaceutical companies ranked by the number of drug candidates in their pipeline. 🏆
#biotech #biopharma #pharma
Check out the latest data from the Citeline Pharma R&D Review 2024, showcasing the top global pharmaceutical companies ranked by the number of drug candidates in their pipeline. 🏆
#biotech #biopharma #pharma
March 18, 2025 at 9:00 AM
Top Pharma Companies by 2024 Pipeline Size 🧬
Check out the latest data from the Citeline Pharma R&D Review 2024, showcasing the top global pharmaceutical companies ranked by the number of drug candidates in their pipeline. 🏆
#biotech #biopharma #pharma
Check out the latest data from the Citeline Pharma R&D Review 2024, showcasing the top global pharmaceutical companies ranked by the number of drug candidates in their pipeline. 🏆
#biotech #biopharma #pharma
New Biologics Companies Launched👇
2024 saw exciting new compaies launched as shown below in the incredible lineup of new and emerging biologic companies in 2024, spanning cell therapy, gene therapy, RNA-based therapeutics, antibodies, and more.
Credit/Source: biopharma
#celltherapy #biopharma
2024 saw exciting new compaies launched as shown below in the incredible lineup of new and emerging biologic companies in 2024, spanning cell therapy, gene therapy, RNA-based therapeutics, antibodies, and more.
Credit/Source: biopharma
#celltherapy #biopharma
March 17, 2025 at 1:01 PM
New Biologics Companies Launched👇
2024 saw exciting new compaies launched as shown below in the incredible lineup of new and emerging biologic companies in 2024, spanning cell therapy, gene therapy, RNA-based therapeutics, antibodies, and more.
Credit/Source: biopharma
#celltherapy #biopharma
2024 saw exciting new compaies launched as shown below in the incredible lineup of new and emerging biologic companies in 2024, spanning cell therapy, gene therapy, RNA-based therapeutics, antibodies, and more.
Credit/Source: biopharma
#celltherapy #biopharma
🚨 BREAKING: Scientists Achieve Removal of Extra Chromosome in Down Syndrome! 🧬
Major milestone as researchers have used CRISPR-Cas9 technology to remove the extra copy of chromosome 21 in human cells—marking a significant step forward in genetic research!
🔗 Read the full article: buff.ly/yC4CZji
Major milestone as researchers have used CRISPR-Cas9 technology to remove the extra copy of chromosome 21 in human cells—marking a significant step forward in genetic research!
🔗 Read the full article: buff.ly/yC4CZji
March 17, 2025 at 9:00 AM
🚨 BREAKING: Scientists Achieve Removal of Extra Chromosome in Down Syndrome! 🧬
Major milestone as researchers have used CRISPR-Cas9 technology to remove the extra copy of chromosome 21 in human cells—marking a significant step forward in genetic research!
🔗 Read the full article: buff.ly/yC4CZji
Major milestone as researchers have used CRISPR-Cas9 technology to remove the extra copy of chromosome 21 in human cells—marking a significant step forward in genetic research!
🔗 Read the full article: buff.ly/yC4CZji
Save the date! The London Biotechnology Show returns on 18-19 June 2025 at ExCeL London. 📷
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
March 13, 2025 at 4:27 PM
Save the date! The London Biotechnology Show returns on 18-19 June 2025 at ExCeL London. 📷
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
𝐀𝐥𝐥 𝐜𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐈𝐦𝐦𝐮𝐧𝐞 𝐒𝐲𝐬𝐭𝐞𝐦:
The immune system is a complex network of cells, tissues, and organs that defends the body against pathogens like bacteria, viruses, fungi, and parasites.
Source: BioTecNika
#immunology #oncology #biotech #celltherapy
The immune system is a complex network of cells, tissues, and organs that defends the body against pathogens like bacteria, viruses, fungi, and parasites.
Source: BioTecNika
#immunology #oncology #biotech #celltherapy
March 4, 2025 at 3:27 PM
𝐀𝐥𝐥 𝐜𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐈𝐦𝐦𝐮𝐧𝐞 𝐒𝐲𝐬𝐭𝐞𝐦:
The immune system is a complex network of cells, tissues, and organs that defends the body against pathogens like bacteria, viruses, fungi, and parasites.
Source: BioTecNika
#immunology #oncology #biotech #celltherapy
The immune system is a complex network of cells, tissues, and organs that defends the body against pathogens like bacteria, viruses, fungi, and parasites.
Source: BioTecNika
#immunology #oncology #biotech #celltherapy
Companies Focused on Neuroinflammatory Targets 👇
72 biopharmaceutical companies below categorised by Preclinical to Phase III and based in therapeutic areas such as CNS, Gene Therapy and iPSCs.
- NLPR 3
- PGRN
- TREM2
- Other
#neurology #biotech #genetherapy #biopharma
72 biopharmaceutical companies below categorised by Preclinical to Phase III and based in therapeutic areas such as CNS, Gene Therapy and iPSCs.
- NLPR 3
- PGRN
- TREM2
- Other
#neurology #biotech #genetherapy #biopharma
March 4, 2025 at 3:25 PM
Companies Focused on Neuroinflammatory Targets 👇
72 biopharmaceutical companies below categorised by Preclinical to Phase III and based in therapeutic areas such as CNS, Gene Therapy and iPSCs.
- NLPR 3
- PGRN
- TREM2
- Other
#neurology #biotech #genetherapy #biopharma
72 biopharmaceutical companies below categorised by Preclinical to Phase III and based in therapeutic areas such as CNS, Gene Therapy and iPSCs.
- NLPR 3
- PGRN
- TREM2
- Other
#neurology #biotech #genetherapy #biopharma
Biopharma M&A Heats Up:
Top 20 Deals by Valuation (2023-2025 YTD) 💰💊
The biopharma industry continues its M&A momentum, with oncology, CNS, and I&I emerging as the most sought-after therapeutic areas.
Credit/Source: Bloomberg & Deutsche Bank
#biotech #biopharma #pharmaceuticals #neurology
Top 20 Deals by Valuation (2023-2025 YTD) 💰💊
The biopharma industry continues its M&A momentum, with oncology, CNS, and I&I emerging as the most sought-after therapeutic areas.
Credit/Source: Bloomberg & Deutsche Bank
#biotech #biopharma #pharmaceuticals #neurology
February 22, 2025 at 3:56 PM
Biopharma M&A Heats Up:
Top 20 Deals by Valuation (2023-2025 YTD) 💰💊
The biopharma industry continues its M&A momentum, with oncology, CNS, and I&I emerging as the most sought-after therapeutic areas.
Credit/Source: Bloomberg & Deutsche Bank
#biotech #biopharma #pharmaceuticals #neurology
Top 20 Deals by Valuation (2023-2025 YTD) 💰💊
The biopharma industry continues its M&A momentum, with oncology, CNS, and I&I emerging as the most sought-after therapeutic areas.
Credit/Source: Bloomberg & Deutsche Bank
#biotech #biopharma #pharmaceuticals #neurology
Visualizing smLiveFISH-labelled MAP1B RNAs in Live Cells using CRISPR-csm.
#genetherapy #biotech #biopharma #crispr
#genetherapy #biotech #biopharma #crispr
February 22, 2025 at 3:54 PM
Visualizing smLiveFISH-labelled MAP1B RNAs in Live Cells using CRISPR-csm.
#genetherapy #biotech #biopharma #crispr
#genetherapy #biotech #biopharma #crispr
Save the date! The London Biotechnology Show returns on 18-19 June 2025 at ExCeL London. 📷
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
February 18, 2025 at 7:16 PM
Save the date! The London Biotechnology Show returns on 18-19 June 2025 at ExCeL London. 📷
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
Connect, innovate & shape the future of biotech!
Register now: tinyurl.com/sscbx4nn
Algae Biotechnology Market 👇
Here’s a quick look at key algae biotechnology companies by region—spanning North America, Europe, and Asia—as highlighted in this visual by BioKnow. 🚀
#algae #biotech #biopharma
Here’s a quick look at key algae biotechnology companies by region—spanning North America, Europe, and Asia—as highlighted in this visual by BioKnow. 🚀
#algae #biotech #biopharma
February 17, 2025 at 3:00 PM
Algae Biotechnology Market 👇
Here’s a quick look at key algae biotechnology companies by region—spanning North America, Europe, and Asia—as highlighted in this visual by BioKnow. 🚀
#algae #biotech #biopharma
Here’s a quick look at key algae biotechnology companies by region—spanning North America, Europe, and Asia—as highlighted in this visual by BioKnow. 🚀
#algae #biotech #biopharma
Global Pharma Leaders of 2024:
A Billion-Dollar Industry on the Rise 👇
🔹 Johnson & Johnson leads the pack with an impressive $88.8 billion in revenue.
🔹 Pfizer, Merck, and AbbVie follow closely, with revenues exceeding $55 billion each.
#pharma #biopharma
A Billion-Dollar Industry on the Rise 👇
🔹 Johnson & Johnson leads the pack with an impressive $88.8 billion in revenue.
🔹 Pfizer, Merck, and AbbVie follow closely, with revenues exceeding $55 billion each.
#pharma #biopharma
February 16, 2025 at 4:00 PM
Global Pharma Leaders of 2024:
A Billion-Dollar Industry on the Rise 👇
🔹 Johnson & Johnson leads the pack with an impressive $88.8 billion in revenue.
🔹 Pfizer, Merck, and AbbVie follow closely, with revenues exceeding $55 billion each.
#pharma #biopharma
A Billion-Dollar Industry on the Rise 👇
🔹 Johnson & Johnson leads the pack with an impressive $88.8 billion in revenue.
🔹 Pfizer, Merck, and AbbVie follow closely, with revenues exceeding $55 billion each.
#pharma #biopharma
Global ADC Market 👇
The #ADC market is experiencing rapid growth, with forecasts indicating a global market size exceeding $18B by 2025, driven by the increasing adoption of targeted #cancer #therapies and the success of key ADCs.
Credits: PharmaSights, Alexander Bonebakker
The #ADC market is experiencing rapid growth, with forecasts indicating a global market size exceeding $18B by 2025, driven by the increasing adoption of targeted #cancer #therapies and the success of key ADCs.
Credits: PharmaSights, Alexander Bonebakker
February 13, 2025 at 11:45 AM
Global ADC Market 👇
The #ADC market is experiencing rapid growth, with forecasts indicating a global market size exceeding $18B by 2025, driven by the increasing adoption of targeted #cancer #therapies and the success of key ADCs.
Credits: PharmaSights, Alexander Bonebakker
The #ADC market is experiencing rapid growth, with forecasts indicating a global market size exceeding $18B by 2025, driven by the increasing adoption of targeted #cancer #therapies and the success of key ADCs.
Credits: PharmaSights, Alexander Bonebakker
2024 FDA Oncology Approvals ✅
The FDA approved 50 novel drugs last year, with oncology and hematology leading. A key approval was Datroway (datopotamab deruxtecan) for metastatic HR-positive, HER2-negative breast cancer.
Credit: Maryam Daneshpour
#oncology #immunotherapy
The FDA approved 50 novel drugs last year, with oncology and hematology leading. A key approval was Datroway (datopotamab deruxtecan) for metastatic HR-positive, HER2-negative breast cancer.
Credit: Maryam Daneshpour
#oncology #immunotherapy
February 12, 2025 at 9:02 AM
2024 FDA Oncology Approvals ✅
The FDA approved 50 novel drugs last year, with oncology and hematology leading. A key approval was Datroway (datopotamab deruxtecan) for metastatic HR-positive, HER2-negative breast cancer.
Credit: Maryam Daneshpour
#oncology #immunotherapy
The FDA approved 50 novel drugs last year, with oncology and hematology leading. A key approval was Datroway (datopotamab deruxtecan) for metastatic HR-positive, HER2-negative breast cancer.
Credit: Maryam Daneshpour
#oncology #immunotherapy
Radiopharma Market 👇
The graph shows a list of FDA-approved radiopharmaceuticals in compliance with USP <825> standards.
The #nuclear medicine market is experiencing rapid growth and projected to reach USD $13.10B by 2032, with a CAGR of 9.10%.
#oncology #radiopharma
The graph shows a list of FDA-approved radiopharmaceuticals in compliance with USP <825> standards.
The #nuclear medicine market is experiencing rapid growth and projected to reach USD $13.10B by 2032, with a CAGR of 9.10%.
#oncology #radiopharma
February 11, 2025 at 9:00 AM
Radiopharma Market 👇
The graph shows a list of FDA-approved radiopharmaceuticals in compliance with USP <825> standards.
The #nuclear medicine market is experiencing rapid growth and projected to reach USD $13.10B by 2032, with a CAGR of 9.10%.
#oncology #radiopharma
The graph shows a list of FDA-approved radiopharmaceuticals in compliance with USP <825> standards.
The #nuclear medicine market is experiencing rapid growth and projected to reach USD $13.10B by 2032, with a CAGR of 9.10%.
#oncology #radiopharma
2024 FDA Large Molecule Drug Approvals
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
February 5, 2025 at 3:00 PM
2024 FDA Large Molecule Drug Approvals
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
2024 FDA Large Molecule Drug Approvals
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
January 29, 2025 at 9:07 PM
2024 FDA Large Molecule Drug Approvals
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
Total Approvals: 19 large molecules, 38% of total FDA approvals.
First-in-Class: 58% (11 out of 19)
Breakthrough Therapy: 42% (9 out of 19)
Source/Credit: Drug Hunter
#oncology #immunology #biotech #biopharma
𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐡𝐚𝐫𝐞 👇
We’re thrilled to announce our partnership with PharmaSights/Alexander Bonebakker to bring you an exclusive series of market maps categorized by drug modality.
#oncology #immunotherapy #biotech
We’re thrilled to announce our partnership with PharmaSights/Alexander Bonebakker to bring you an exclusive series of market maps categorized by drug modality.
#oncology #immunotherapy #biotech
January 29, 2025 at 9:00 AM
𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐡𝐚𝐫𝐞 👇
We’re thrilled to announce our partnership with PharmaSights/Alexander Bonebakker to bring you an exclusive series of market maps categorized by drug modality.
#oncology #immunotherapy #biotech
We’re thrilled to announce our partnership with PharmaSights/Alexander Bonebakker to bring you an exclusive series of market maps categorized by drug modality.
#oncology #immunotherapy #biotech
#ADCs for Lung Cancer
High Prevalence Targets:
TROP2 (≥89%), #EGFR (~60%), and ROR1 (~94%) are widely expressed in lung #cancer, making them key drug targets.
Emerging Targets:
CEACAM5 (24%) and B7-H3 (~80%) are promising for specific lung cancer subtypes.
#immunotherapy
High Prevalence Targets:
TROP2 (≥89%), #EGFR (~60%), and ROR1 (~94%) are widely expressed in lung #cancer, making them key drug targets.
Emerging Targets:
CEACAM5 (24%) and B7-H3 (~80%) are promising for specific lung cancer subtypes.
#immunotherapy
January 26, 2025 at 11:00 AM
#ADCs for Lung Cancer
High Prevalence Targets:
TROP2 (≥89%), #EGFR (~60%), and ROR1 (~94%) are widely expressed in lung #cancer, making them key drug targets.
Emerging Targets:
CEACAM5 (24%) and B7-H3 (~80%) are promising for specific lung cancer subtypes.
#immunotherapy
High Prevalence Targets:
TROP2 (≥89%), #EGFR (~60%), and ROR1 (~94%) are widely expressed in lung #cancer, making them key drug targets.
Emerging Targets:
CEACAM5 (24%) and B7-H3 (~80%) are promising for specific lung cancer subtypes.
#immunotherapy
RNA Therapeutics Landscape
77 companies below in the RNA industry who are public, broken down by drug development stage. 14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
77 companies below in the RNA industry who are public, broken down by drug development stage. 14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
January 26, 2025 at 9:00 AM
RNA Therapeutics Landscape
77 companies below in the RNA industry who are public, broken down by drug development stage. 14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
77 companies below in the RNA industry who are public, broken down by drug development stage. 14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
RNA Therapeutics Landscape
77 companies below in the RNA industry who are public, broken down by drug development stage.
14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
77 companies below in the RNA industry who are public, broken down by drug development stage.
14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
January 25, 2025 at 3:42 PM
RNA Therapeutics Landscape
77 companies below in the RNA industry who are public, broken down by drug development stage.
14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
77 companies below in the RNA industry who are public, broken down by drug development stage.
14 marketed RNA products. Great to see.
What do you think?
Source: TD Cowen for the graphic
#RNA #biopharma #biotech #pharma
Cancer chemotherapy drugs by their mechanisms of action and therapeutic uses.
Each category includes drugs, their mechanisms (e.g., DNA damage, cell division inhibition), and their specific cancer applications.
#oncology #chemotherapy #biotech #biopharma
Each category includes drugs, their mechanisms (e.g., DNA damage, cell division inhibition), and their specific cancer applications.
#oncology #chemotherapy #biotech #biopharma
January 22, 2025 at 2:07 AM
Cancer chemotherapy drugs by their mechanisms of action and therapeutic uses.
Each category includes drugs, their mechanisms (e.g., DNA damage, cell division inhibition), and their specific cancer applications.
#oncology #chemotherapy #biotech #biopharma
Each category includes drugs, their mechanisms (e.g., DNA damage, cell division inhibition), and their specific cancer applications.
#oncology #chemotherapy #biotech #biopharma
In 2024, the FDA approved 50 new drugs, with over half targeting rare diseases, suggesting 'small markets' are becoming key opportunities for the pharmaceutical industry.
What trends stood out to you this year?
Source/Credit @ Chris De Savi
#biotech #biopharma #FDA approvals
What trends stood out to you this year?
Source/Credit @ Chris De Savi
#biotech #biopharma #FDA approvals
January 21, 2025 at 12:10 AM
In 2024, the FDA approved 50 new drugs, with over half targeting rare diseases, suggesting 'small markets' are becoming key opportunities for the pharmaceutical industry.
What trends stood out to you this year?
Source/Credit @ Chris De Savi
#biotech #biopharma #FDA approvals
What trends stood out to you this year?
Source/Credit @ Chris De Savi
#biotech #biopharma #FDA approvals
